Trial Profile
A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Efficacy of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) and Active Rabies Vaccine in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Rabies immune globulin (Primary) ; Rabies vaccine
- Indications Rabies
- Focus Pharmacodynamics; Registrational
- Sponsors Kamada
- 31 Aug 2021 Status changed from active, no longer recruiting to completed.
- 29 Oct 2019 Results published in the Kamada, Kedrion Biopharma Media Release
- 29 Oct 2019 According to an Kamada, Kedrion Biopharma media release, results from this study were in Human Vaccines & Immunotherapeutics Medical Journal.